Client: Harwell Campus
Programme: 86 Weeks
The Catalent facility, acquired from Vaccine Manufacturing Innovation Centre (VMIC), will be used for the development and manufacture of biologic therapies and vaccines, including mRNA, proteins, and other advanced modalities.
From the initial project stages where the brownfield site required extensive geotechnical investigation and remediation to the creation of a heavily serviced, controlled environment with intricate M&E requirements, this has been a complex and challenging project which has seen our team rise to the task in the delivery of a cutting edge facility.
|Client/End User:||Harwell Campus|
“This is Harwell’s first collaboration with Glencar and the experience on VMIC Project thus far has been remarkable. They bring all the ingredients required to manufacture successful project outcomes. The proactiveness, dynamicity and problem solving skills have been outstanding whilst bringing all the resources necessary to successfully achieve the set targets. They are client focused, managing difficult situations and relationships as expected. It’s been a pleasure working with the team to date on what is a rather special/unprecedented and challenging project."
Cliff Dare, Harwell.
RELATED CASE STUDIES
The Vaccine Manufacturing & Innovation Centre (VMIC) in Oxfordshire is to become the first-ever facility dedicated for the development and manufacturing of vaccines in the UK, upon...